Electra Therapeutics Inc is a United States-based clinical- stage biotechnology company. The Company is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Its ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells and precisely depletes pathological immune cells.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-08	US$9.140	-0.22%	408,048
26-10-07	US$9.160	-6.72%	407,261
26-10-06	US$9.820	+0.82%	276,154
26-10-05	US$9.740	-6.08%	334,447
26-10-02	US$10.37	-2.90%	696,581

Delayed Quote Nasdaq

More quotes

Market Closed - Nasdaq 16:00:00 2026-10-08 EDT			5-day change	1st Jan Change
9.140 ^USD	-0.22%		-18.76%	-

09-25	ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO	RE
09-25	ADARx Pharmaceuticals raises $446.3 million in upsized US IPO	RE

Markets		Quality
Nasdaq	ETRA	Delayed
CBOE	ETRA	Real-time

09-25	ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO	RE
09-25	ADARx Pharmaceuticals raises $446.3 million in upsized US IPO	RE
09-21	Drug developer ADARx seeks $1.74 billion valuation in US IPO	RE
09-20	Electra Therapeutics, Inc.(NasdaqGS:ETRA) added to NASDAQ Composite Index	CI
09-18	Electra Therapeutics IPO Expected to Raise $350 Million	MT
09-17	Electra Therapeutics, Inc. has completed an IPO in the amount of $350.00001 million.	CI
08-28	Electra Therapeutics, Inc. has filed an IPO in the amount of $100 million.	CI
08-09	Electra Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI

1 day	-0.22%
1 week	-18.76%
Current month	-18.76%

Electra Therapeutics, Inc. Stock

Stocks

ETRA

US2848251060

Biotechnology & Medical Research

Chart: Electra Therapeutics, Inc.

Latest news: Electra Therapeutics, Inc.

Press Releases: Electra Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Electra Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	8.63	11.13
1 month	8.63	15.5
Current year	8.63	15.5
1 year	8.63	15.5
3 years	8.63	15.5
5 years	8.63	15.5
10 years	8.63	15.5

Manager	Title	Age	Since
Que Huong Dong CEO	Chief Executive Officer	44	2023-09-30
Chris Clark DFI	Director of Finance/CFO	48	2025-11-30
Graham Parry CTO	Chief Tech/Sci/R&D Officer	62	2023-11-30

Director	Title	Age	Since
Nancy Stagliano CHM	Chairman	59	2019-02-28
Beth Seidenberg BRD	Director/Board Member	69	2019-02-28
Carl Gordon BRD	Director/Board Member	61	2019-02-28

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/21/26	Westlake Biopartners LLC	Other	Company	6,347,539	16.0968%
9/21/26	Que Huong Dong	Conversion	Chief Executive Officer	910,968	2.3101%
9/21/26	OrbiMed Advisors Private Equity	Conversion	Company	12,437,007	31.5391%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELECTRA THERAPEUTICS, INC.	-0.22%	-18.76%	-	-	575M
WUXI APPTEC CO., LTD.	-3.19%	-3.19%	+44.60%	+87.98%	74.68B
ARGENX SE	-15.86%	-16.67%	+3.92%	+50.90%	58.7B
LONZA GROUP AG	-2.39%	-2.05%	+4.29%	+31.33%	48.36B
REVOLUTION MEDICINES, INC.	-6.35%	-8.35%	+303.95%	+651.28%	43.05B
IQVIA HOLDINGS INC.	+0.30%	-3.71%	+28.89%	+30.33%	42.48B
BEONE MEDICINES AG	-3.82%	-4.32%	+2.49%	+101.36%	41.39B
CELLTRION, INC.	-2.13%	+1.07%	+7.51%	+50.31%	31.29B
BIONTECH SE	-3.35%	-6.35%	-13.20%	-17.22%	23.93B
INSMED INCORPORATED	-1.24%	-11.97%	-38.10%	+311.13%	22.22B
Average	-3.81%	-4.22%	+38.26%	+144.16%	38.67B
Weighted average by Cap.	-4.84%	-1.90%	+44.70%	+136.42%

	2024	2025
Net sales	-	-
Net income	-24.79M -22.13M -20.65M -18.76M -35.3M -2.4B -35.64M -248M -96.96M -1.22B -93.06M -91.04M -3.92B	-61.98M -55.34M -51.63M -46.9M -88.25M -6B -89.11M -620M -242M -3.05B -233M -228M -9.81B
Net Debt	-	-